Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1205 vs Lucentis for macular edema due to retinal vein occlusion
ChiCTR2500113142Phase 4Not yet recruiting
- Sponsor
- Bengbu Second People's Hospital
- Start
- Nov 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of QL1205 and ranibizumab in Vein occlusion (RVO) (2 arms), sponsored by Bengbu Second People's Hospital. Primary endpoint: Best-corrected visual acuity. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
QL1205ranibizumab
03
Conditions
Vein occlusion (RVO)
Beyond the preview
Go deeper on ChiCTR2500113142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113142.